Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 01 - 25 save search
MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
Published: 2021-01-25 (Crawled : 23:00) - biospace.com/
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: 0.72%
H: 1.98%
C: -4.8%
cancer phase 3 phase 1 phase 2
I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer
Published: 2021-01-25 (Crawled : 22:00) - biospace.com/
MOR | News | $18.04 0.45% 0.44% 180K
|
Health Technology
|
| O: 1.63%
H: 0.57%
C: -0.27%
IMAB | $1.81 0.56% 0.55% 200K
|
Health Technology
|
| O: 0.72%
H: 1.98%
C: -4.8%
cancer phase 3 phase 1 phase 2
Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid Tumors
Published: 2021-01-25 (Crawled : 19:00) - biospace.com/
EXEL | $23.295 1.86% 1.82% 1.9M
|
Health Technology
|
| O: 0.36%
H: 3.96%
C: 2.7%
cancer trial phase 3 phase 1 phase 2 solid tumors
Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan
Published: 2021-01-25 (Crawled : 18:00) - biospace.com/
DVAX | $11.75 -0.76% -0.77% 1.4M
|
Health Technology
|
| O: -0.03%
H: 25.9%
C: 25.52%
covid phase 2 vaccine trial
DURECT Corporation Announces First Patient Dosed in Phase 2b AHFIRM Study of DUR-928 in Severe Alcohol-Associated Hepatitis
Published: 2021-01-25 (Crawled : 17:00) - biospace.com/
DRRX | $0.851 5.71% 5.41% 30K
|
Health Technology
|
| O: 3.56%
H: 3.22%
C: 2.58%
phase 2 hepatitis phase 2b
Alector Announces First Participant Dosed in Phase 2 Study Evaluating AL002 in Individuals with Early Alzheimer’s Disease
Published: 2021-01-25 (Crawled : 14:00) - globenewswire.com
ALEC | $5.33 3.1% 3.0% 550K
|
Health Technology
|
| O: 3.68%
H: 5.76%
C: 5.52%
disease alzheimer phase 2 alzheimer’s alzheimer's disease alzheimer's
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Published: 2021-01-25 (Crawled : 13:00) - biospace.com/
ARWR | $23.775 -0.61% -0.61% 830K
|
Health Technology
|
| O: -0.27%
H: 3.45%
C: 2.79%
phase 2 treatment phase 2b
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.